Next 10 |
ARK Invest’s 13F portfolio value decreased from $23.96B to $16.91B this quarter. Coinbase Global, Roku, Shopify, and Ginkgo Bioworks were increased while decreasing Spotify, Ionis Pharma, Vertex Pharma, and Sea Limited. The top three positions are Tesla, Zoom Video, and Rok...
BILLERICA, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its financial results for the second quarter ended June 30, 2022, after the mark...
BILLERICA, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical device company that features personalized knee and hip replacement products, today announced results of a published study that investigated the characteristic shapes of knees to see if typica...
BILLERICA, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today that Mark Augusti, Chief Executive Officer, and Bob Howe, Chief Financial Officer, will part...
Conformis, Inc. (CFMS) Q1 2022 Earnings Conference Call May 04, 2022 08:30 AM ET Company Participants Mark Augusti - President and Chief Executive Officer Bob Howe - Chief Financial Officer Conference Call Participants Steven Lichtman - Oppenheimer & Company Josh Jennings - Cowen Presenta...
ConforMIS press release (NASDAQ:CFMS): Q1 GAAP EPS of -$0.09 misses by $0.02. Revenue of $15.6M (+12.7% Y/Y) beats by $1.59M. Outlook: "We expect our second quarter product revenue to be in the range of $14.5 million to $15.5 million. The second quarter revenue range does not assume impr...
BILLERICA, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the first quarter ended March 31, 2022. First Quarter 2022 ...
ConforMIS (NASDAQ:CFMS) is scheduled to announce Q1 earnings results on Wednesday, May 4th, before market open. The consensus EPS Estimate is -$0.07 (+22.2% Y/Y) and the consensus Revenue Estimate is $14.01M (+1.2% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions and 1...
ABC,AMRN,AMRX,ASC,ATI,AVA,AVNS,BDC,BIP,BLX,BRKR,BRY,BWA,CDW,CFMS,CGAU,CLDT,CLH,CLVS,CMLS,CRL,CRTO,CSII,CVS,DCPH,DIN,DOC,OTCPK:EADSF,EAT,EDIT,EMR,OTCPK:ENLAY,EXPI,EYPT,FDP,FMS,OTCPK:FSNUF,FTS,FUN,GEL,GNRC,GOLD,GTHX,HZNP,IDXX,IMKTA,INSW,IONS,ISEE,JCI,JHG,OTCPK:LBLCF,LITE,LL,LNG,MAR,MCRB,MFA,MIR...
BILLERICA, Mass., April 11, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS) announced today it will release its financial results for the first quarter ended March 31, 2022, before the market opens on Wednesday, May 4, 2022, at approximately 7:00 a.m. Eastern Time. Mark August...
News, Short Squeeze, Breakout and More Instantly...
BILLERICA, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its financial results for the second quarter ended June 30, 2022, after the mark...
BILLERICA, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical device company that features personalized knee and hip replacement products, today announced results of a published study that investigated the characteristic shapes of knees to see if typica...
BILLERICA, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today that Mark Augusti, Chief Executive Officer, and Bob Howe, Chief Financial Officer, will part...